A novel bivalent single-chain variable fragment (scFV) inhibits the action of tumour necrosis factor alpha.
Suppression of TNFalpha (tumour necrosis factor alpha) activity is widely considered to be among the most efficient treatments available for chronic inflammatory diseases. Here, a bivalent scFv (single-chain variable fragment) fragment, named TNF-BAb, was engineered by fusing two anti-TNFalpha scFV fragments in tandem via a long and flexible linking peptide derived from human serum albumin and produced in functional form from Escherichia coli inclusion bodies. The bioactivity assays demonstrated that TNF-BAb gained enormously in avidity and showed a much stronger ability to inhibit the biological action of TNFalpha, indicating that TNF-BAb may become a good candidate for anti-TNFalpha therapy.
Liu
Mengyuan
M
Center for Infection and Immunity Research, School of Life Sciences, Hubei University, Wuhan 430062, People's Republic of China.
Wang
Xiangbin
X
Yin
Changcheng
C
Zhang
Zhong
Z
Lin
Qing
Q
Zhen
Yongsu
Y
Huang
Hualiang
H
D000818:Animals; D000937:Antigen-Antibody Reactions; D001483:Base Sequence; D002460:Cell Line; D002846:Chromatography, Affinity; D002850:Chromatography, Gel; D017931:DNA Primers; D004591:Electrophoresis, Polyacrylamide Gel; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007128:Immunoglobulin Fragments / Q000276:immunology*; D051379:Mice; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology
D017931:DNA Primers; D007128:Immunoglobulin Fragments; D014409:Tumor Necrosis Factor-alpha